- Conditions
- Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Interventions
- Gabapentin, Methadone, Oxycodone, Quality-of-Life Assessment, Questionnaire Administration, Venlafaxine, Venlafaxine Hydrochloride Extended Release
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Buffalo, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 328
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Esophageal Cancer
- Interventions
- conventional surgery, positron emission tomography, radionuclide imaging, fludeoxyglucose F 18, chemotherapy, Radiotherapy
- Procedure · Radiation · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 26 more
- Conditions
- Head and Neck Cancer
- Interventions
- gemcitabine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Burlington, Massachusetts + 1 more
- Conditions
- Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasal Cavity Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasal Cavity Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8
- Interventions
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomography, Positron Emission Tomography, Tumor Resection
- Biological · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 12
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 8 more
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Esophageal Carcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Locally Advanced Urothelial Carcinoma, Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Cutaneous Melanoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Cutaneous Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Interventions
- Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration
- Other · Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Head and Neck Cancer
- Interventions
- capecitabine, oxaliplatin
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ivonescimab, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
- Procedure · Biological
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- capecitabine, carboplatin, epirubicin hydrochloride
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Portsmouth, Virginia
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- tanespimycin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Head and Neck Cancer
- Interventions
- cisplatin, docetaxel, 5-fluorouracil, surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 74
- States / cities
- Norwich, Connecticut • Aurora, Illinois • Chicago, Illinois + 51 more
- Conditions
- Head and Neck Cancer
- Interventions
- DNA Microarray analysis, MALDI-TOF mass spectrometry, DNA microarray and MALDI-TOF mass spectrometry
- Genetic
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Solid Tumor
- Interventions
- questionnaire administration, survey administration, quality-of-life assessment
- Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Interventions
- Cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 15
- States / cities
- Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 11 more
- Conditions
- Head and Neck Cancer
- Interventions
- thalidomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Tongue Cancer
- Interventions
- cetuximab, cisplatin, external beam radiation therapy, laboratory biomarker analysis
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Head and Neck Cancer
- Interventions
- carboplatin, paclitaxel, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 47
- States / cities
- Jacksonville, Florida • Lakeland, Florida • Chicago, Illinois + 28 more
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Radiation Toxicity
- Interventions
- amifostine trihydrate, cisplatin, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
- Interventions
- ABBV-400, Itraconazole (ITZ), Bevacizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 20
- States / cities
- Duarte, California • San Francisco, California • Aurora, Colorado + 15 more
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III, Head and Neck Cancer Stage IV, Head and Neck Cancer Metastatic, Cancer, Cancer of Esophagus, Cancer, Metastatic, Cancer of Head and Neck, Cancer of Mouth, Cancer of Neck
- Interventions
- Pembrolizumab, Tadalafil
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Cancer
- Interventions
- monoclonal antibody RAV12
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
- Conditions
- Head and Neck Cancer
- Interventions
- cetuximab, cisplatin
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 73
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 54 more
- Conditions
- Head and Neck Cancer, Skin Reactions Secondary to Radiation Therapy
- Interventions
- Biafine cream, quality-of-life assessment, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 0 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 240
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more
- Conditions
- Head and Neck Cancer
- Interventions
- cisplatin, paclitaxel, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 21 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 215
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
- Interventions
- cetuximab, paclitaxel, carboplatin, erlotinib hydrochloride, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 3
- States / cities
- Rochester, New York • Philadelphia, Pennsylvania • Dallas, Texas